United States · Funded startup

Who invested in Aledade

6 rounds we have observed, with the 9 investors named in them. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.

BiotechHealthcare

Raised 11 months agoValuation: $3.5B, Mar 2026

Funding summaryUpdated 26 Oct 2026

$598Mraised across 6 rounds since 2014, from 6 sources

$4.5MSeries A$30MSeries B$20MSeries B$20MSeries D$23MRound$500MDebt
Latest round
Debt, $500MDec 2025
Step-upi
21.7×
Investors
9
See who backed them

The funding story

Each circle is a round, placed by date and sized by amount. The line above is the running total.

201420162018202020222024
$4.5MSeries A$30MSeries B$20MSeries B$20MSeries D$23MRound$500MDebt
First round
Series A, $4.5M
Jun 2014
Biggest round
$500M
Debt · Dec 2025
Usual gap between rounds
19 months
the median of 5

The rounds

  1. Dec 2025
  2. Oct 2018
    Round$23M2 returning

    Reported by AxiosSEC filing: $46M sold, first sale Dec 2017

  3. Mar 2017
    Series D$20M3 new1 returning

    Reported by BaltimoreSEC filing: $40M sold, first sale Dec 2016

  4. Jan 2017
    Series B$20M1 new

    Reported by FinSMEsSEC filing: $20M sold, first sale Dec 2016

  5. Jun 2015
    Series B$30M1 new1 returning

    From a historical funding recordSEC filing: $15M sold, first sale May 2015

  6. Jun 2014
    Series A$4.5M1 new

    From a historical funding recordSEC filing: $4.5M sold, first sale Jun 2014

Founders and team

From Aledade's own website and the SEC filings it signed: 2 founders, 12 on the team.

Farzad MostashariChief Executive Officer and Co-FounderNamed on its 2023 Form D
Mat KendallPresident and Co-Founder
  • Ahmed HaqueChief Performance Officer
  • Daren ThayneChief Technology Officer
  • Gui WoolstonChief Analytics Officer
  • Jessica SomersChief Financial Officer
  • Kim WittmanChief People Officer
  • Oraida RomanChief Commercial Officer
  • Rosemary WeldonChief Product Officer
  • Sashi MoodleyChief Medical Officer
  • Sean CavanaughChief Policy Officer
  • John DoyleChief Strategy Officer
  • Phuong PhillipsChief Legal Officer
  • Matthew KendallExecutive Officeri

On the board, as filediBijan SalehizadehDavid BlumenthalJulie SunderlandMichelle RyanPaul HennessyPhyllis YaleRobert Kocher

Who was in which round

The busiest backers across the latest rounds. A filled square is a round they joined; a dark one, a round they led.

Series A2014Series B2015Series B2017Series D2017Round2018Debt2025VenrockARCH Venture PartnersBiomatics CapitalLightspeed Venture PartnersTiger Global ManagementIVPMaryland Venture FundArchBiomatics Capital/ GV

Everyone who backed them

VenrockVC firm5rounds
ARCH Venture PartnersVC firm2rounds
Biomatics CapitalVC firm2rounds
IVPVC firm1round
ArchHedge fund1round
Biomatics Capital/ GVno record of our own yet1round

Missing a round, or an investor who was in one? Tell us.

Also claim to have backed them

These 2 firms list Aledade as a portfolio company on their own websites, but no report of a round names them. They are the firms' own claims, kept apart from the rounds above.

Echo Health VenturesPrivate equityPer its own site
Activate Venture PartnersVC firmPer its own site

Quick answers about Aledade

Who invested in Aledade?

Aledade's investors include Venrock, ARCH Venture Partners, Biomatics Capital, Lightspeed Venture Partners and Tiger Global Management, and 4 more on record.

How much has Aledade raised?

Aledade has raised $598M across 6 rounds since 2014.

When did Aledade last raise?

Aledade's most recent round was a Debt of $500M in Dec 2025.

What was Aledade's biggest round?

Its most recent round, $500M in Dec 2025, is also its largest on record.

Who backed Aledade first?

Aledade's first round on record, in Jun 2014, was backed by Venrock.

What stage is Aledade at?

Aledade's latest named round is a Debt, in Dec 2025.

Where is Aledade based?

Aledade is based in the United States.

Companies like Aledade

In the same sector, and raised in the last eighteen months.

Find investors like these

Search every investor by what they have actually funded, then narrow to your stage and market. Free.